22. Moyamoya disease Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 17 Drugs : 22 - (DrugBank : 17) / Drug target genes : 33 - Drug target pathways : 45

Drugs and their primary sponsors and trial info
Aspirin   
   Beijing Tiantan Hospital, Capital Medical University
      2019   -   ChiCTR1800020377   China;
   Capital Medical University
      2019   -   NCT04012268   China;
   Qilu Hospital of Shandong University
      2021   -   ChiCTR2100046178   china;
Desflurane   
   The First Affiliated Hospital of Zhengzhou University
      2019   Phase 4   ChiCTR1900027197   China;
Dl-3-n-butylphthalide (NBP)   
   yuanli Zhao
      2020   Phase 3   NCT04205578   China;
Edaravone   
   Department of Neurosurgery, Hokkaido University Graduate School of Medicine
      2012   -   JPRN-UMIN000008742   Japan;
Erythropoietin   
   Ajou University School of Medicine
      2010   Phase 1/Phase 2   NCT03162588   Korea, Republic of;
   Seoul National University Hospital
      2019   -   NCT03882060   Korea, Republic of;
Fluorescein   
   Akiyama Hideo
      2021   -   JPRN-jRCTs031200402   Japan;
Gadobutrol   
   Aoki Shigeki
      2018   -   JPRN-jRCTs031180017   Japan;
Gadovist   
   Aoki Shigeki
      2018   -   JPRN-jRCTs031180017   Japan;
Indocyanine green   
   Akiyama Hideo
      2021   -   JPRN-jRCTs031200402   Japan;
Magnetic Resonance Imaging   
   Stanford University
      2009   -   NCT01419275   United States;
Norepinephrine   
   The South District of Anhui Provincial Hospital
      2021   Phase 4   ChiCTR2000041260   China;
      2020   Phase 4   ChiCTR2000029878   China;
Normal Saline Infusion Solution   
   yuanli Zhao
      2020   Phase 3   NCT04205578   China;
Normal saline   
   Seoul National University Hospital
      2019   -   NCT03882060   Korea, Republic of;
Phenylephrine   
   The South District of Anhui Provincial Hospital
      2021   Phase 4   ChiCTR2000041260   China;
      2020   Phase 4   ChiCTR2000029878   China;
Propofol   
   The First Affiliated Hospital of Zhengzhou University
      2019   Phase 4   ChiCTR1900027197   China;
RIC   
   Capital Medical University
      2019   -   NCT04012268   China;
Sevoflurane   
   Seoul National University Hospital
      2015   -   NCT02510586   -
Water   
   Akiyama Hideo
      2021   -   JPRN-jRCTs031200402   Japan;
Xenon contrast agent   
   Stanford University
      2009   -   NCT01419275   United States;